This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Singapore Pte Ltd.
Reference
Tee A, et al. Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore. Singapore Medical Journal : 16 Mar 2018. Available from: URL: http://doi.org/10.11622/smedj.2018022
Rights and permissions
About this article
Cite this article
Indacaterol/glycopyrronium: better outcomes, lower cost in COPD. PharmacoEcon Outcomes News 800, 22 (2018). https://doi.org/10.1007/s40274-018-4841-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4841-2